期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Prognostic significance of X-ray cross-complementing gene 1 expression in gastric cancer 被引量:2
1
作者 Jian Wang Tongshan Wang +6 位作者 Jun Xu Xiao Li Wen Jiao Chen Wei Shi Jianfeng Cheng Ping Liu xiqiao zhou 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第3期355-361,共7页
Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCCI) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. M... Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCCI) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. Methods: Immunohistochemistry (IHC) was used to evaluate XRCCI protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Among 612 patients staged II/III in our study, 182 (29.74%) were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS (P=0.347) or DFS (P=0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS (P=0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P=0.049). Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS (P〈0.05). Though XRCCI plays an important role in DNA repair pathways, no significant relationship is found in XRCCI expression and OS among gastric cancer in our study. Conclusions: XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy. 展开更多
关键词 Gastric cancer X-ray cross-complementing gene 1 (XRCC1) platinum drugs prognosis
下载PDF
火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病的临床探索
2
作者 谭莹 朱鹏飞 +4 位作者 李楠 黄莉吉 周希乔 严倩华 余江毅 《中华临床医师杂志(电子版)》 CAS 2024年第2期171-177,共7页
目的探讨火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病患者的临床疗效及安全性。方法将江苏省中医院2021年3月至2023年3月门诊或病房收治的高或极高进展风险的糖尿病肾病患者作为研究对象,采用随机数字表法分为对照组和观察组... 目的探讨火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病患者的临床疗效及安全性。方法将江苏省中医院2021年3月至2023年3月门诊或病房收治的高或极高进展风险的糖尿病肾病患者作为研究对象,采用随机数字表法分为对照组和观察组,各55例。对照组给予黄葵胶囊治疗,观察组在对照组治疗的基础上联合火把花根片治疗,2组均治疗6个月。比较2组治疗前后的尿微量蛋白/肌酐比值(UACR)、估算的肾小球滤过率(eGFR)、血肌酐、胱抑素C、肾功能及尿蛋白的疗效评估及不良反应情况。结果观察组治疗后UACR和血肌酐下降,eGFR升高(P均<0.05),胱抑素C呈下降趋势,但无统计学意义(P>0.05);对照组治疗后UACR、血肌酐和eGFR均呈下降趋势,但差异无统计学意义(P均>0.05),胱抑素C上升(P<0.05)。观察组UACR、eGFR、胱抑素C治疗前后的改善幅度(ΔUACR、ΔeGFR和Δ胱抑素C)均明显优于对照组(P均<0.05)。在肾功能疗效评估方面,治疗后观察组显效14例,有效8例,稳定18例,无效12例,总有效率为76.92%;对照组显效6例,有效6例,稳定11例,无效28例,总有效率为45.1%;2组总有效率差异有统计学意义(P<0.05)。在尿蛋白疗效评估方面,治疗后观察组近期缓解14例,显效10例,有效16例,无效12例,总有效率为76.92%;对照组近期缓解8例,显效6例,有效19例,无效18例,总有效率为64.71%;观察组治疗蛋白尿的总有效率高于对照组,但差异无明显统计学意义(P>0.05)。在安全性评价中,观察组患者与对照组患者的不良反应率无明显统计学意义(7.69%vs 3.92%,P>0.05)。结论火把花根片联合黄葵胶囊对高或极高进展风险的糖尿病肾病患者临床疗效显著,安全性较好,在降低尿蛋白和保护肾功能方面具有显著优势,值得临床推广。 展开更多
关键词 糖尿病肾病 火把花根片 黄葵胶囊 临床疗效 安全性
原文传递
纳米脂质体促进柚皮素对弹性蛋白酶诱导的小鼠腹主动脉瘤的抑制作用
3
作者 陈都 鱼毛毛 +5 位作者 张庆义 胡睿 周析巧 邰北 陆有群 祁荣 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2024年第3期201-215,共15页
腹主动脉瘤(AAA)是一种严重的炎症性血管疾病,其特征是基质金属蛋白酶(MMPs)升高、细胞外基质(ECM)降解和血管炎症反应。近年来的研究表明,柚皮素(NGN)作为一种生物活性黄酮,有抑制AAA的作用,但是较低的水溶性及口服吸收特性限制了NGN抑... 腹主动脉瘤(AAA)是一种严重的炎症性血管疾病,其特征是基质金属蛋白酶(MMPs)升高、细胞外基质(ECM)降解和血管炎症反应。近年来的研究表明,柚皮素(NGN)作为一种生物活性黄酮,有抑制AAA的作用,但是较低的水溶性及口服吸收特性限制了NGN抑制AAA的有效性。本研究开发了一种NGN纳米脂质体处方(NGN-NL),以增强NGN对弹性蛋白酶诱导的小鼠AAA的抑制作用。首先,我们优化了NGN-NL的处方,发现磷脂和NGN的比例为9:1时为最佳处方。此外,我们观察到,与脂质体处方中的药物及辅料的物理混合物相比,NGN制备成脂质体后具有更强的抑制LPS诱导的巨噬细胞M1极化的作用。在同等剂量下,NGN-NL可比游离NGN展现出更强的抑制巨噬细胞M1极化的作用。此外,脂质体载体本身也呈现一定程度的抑制M1极化的特性,可协同增强NGN抑制巨噬细胞M1极化的效果。体内研究表明,以含有25mg/kg NGN剂量的NGN-NL对小鼠隔日进行腹腔注射,与游离NGN在使用两倍剂量(50mg/kg)下产生的AAA抑制效率相近。具体表现为:改善腹主动脉直径扩张、保持主动脉结构完整性、减缓弹性蛋白降解、减少巨噬细胞浸润和下调腹主动脉MMP-2和MCP-1的表达。但与NGN-NL相比,同等剂量(25mg/kg)的游离NGN并不能有效抑制AAA的发生和发展。综上所述,NGN-NL显著提高了NGN对小鼠AAA的抑制作用,展现出在其未来在AAA临床治疗中的应用潜力。 展开更多
关键词 纳米脂质体 柚皮素 腹主动脉瘤 炎症
原文传递
Dysregulated bile acid homeostasis:unveiling its role in metabolic diseases 被引量:1
4
作者 Yanyan Wang Huangru Xu +2 位作者 xiqiao zhou Weidong Chen Huiping zhou 《Medical Review》 2024年第4期262-283,共22页
Maintaining bile acid homeostasis is essential for metabolic health.Bile acid homeostasis encompasses a complex interplay between biosynthesis,conjugation,secretion,and reabsorption.Beyond their vital role in digestio... Maintaining bile acid homeostasis is essential for metabolic health.Bile acid homeostasis encompasses a complex interplay between biosynthesis,conjugation,secretion,and reabsorption.Beyond their vital role in digestion and absorption of lipid-soluble nutrients,bile acids are pivotal in systemic metabolic regulation.Recent studies have linked bile acid dysregulation to the pathogenesis of metabolic diseases,including obesity,type 2 diabetes melli-tus(T2DM),and metabolic dysfunction-associated steatotic liver disease(MASLD).Bile acids are essential signaling molecules that regulate many critical biological processes,including lipid metabolism,energy expenditure,insulin sensitivity,and glucose metabolism.Disruption in bile acid homeostasis contributes to metabolic disease via altered bile acid feedback mechanisms,hormonal dysregu-lation,interactions with the gut microbiota,and changes in the expression and function of bile acid transporters and receptors.This review summarized the essential molecular pathways and regulatory mechanisms through which bile acid dysregulation contributes to the pathogenesis and progression of obesity,T2DM,and MASLD.We aim to underscore the significance of bile acids as potential diag-nostic markers and therapeutic agents in the context of metabolic diseases,providing insights into their application in translational medicine. 展开更多
关键词 bile acids metabolic diseases OBESITY takeda G protein-coupled receptor 5 type 2 diabetes mellitus metabolic dysfunction-associated steatotic liver disease
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部